搜索替代詞:
cancer reveal » cancer reveals (擴展搜索), cancer revealed (擴展搜索), cancers reveals (擴展搜索)
cancer ready » cancer real (擴展搜索), cancer renal (擴展搜索)
transl lung » transoral lung (擴展搜索), transl dunja (擴展搜索), cranial lung (擴展搜索)
cancer read » cancer real (擴展搜索), cancer spread (擴展搜索), cancer renal (擴展搜索)
cancer res » cancer re (擴展搜索), cancer real (擴展搜索), cancer result (擴展搜索)
A mostrar 1 - 20 resultados de 1,936 para a pesquisa 'transl lung ((cancer res) OR (((((cancer read) OR (cancer ready))) OR (cancer reveal))))', 查詢時間: 1.57seg Refinar resultados
Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials—are we in a new era?
Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis

Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy
Prognostic markers in lung cancer: is it ready for prime time?

let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis
microRNA expression pattern as an ancillary prognostic signature for radiotherapy

Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?
The combination strategies will be ready the right first-line choice for squamous lung cancer patients?

The “liquid biopsy” in non-small cell lung cancer – not quite ready for prime time use
Perifissural nodules: ready for application into lung cancer CT screening?

Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway
Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?

Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?

Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility

檢索工具: 得到RSS訂閱 — 推薦此搜索 — 保存搜索